Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Investor A | BATS Europe | Financial | Investment Holding Companies | €78.46B | 4.5x | 0.15 | €23.18 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
NVIDIA | Frankfurt | Technology | Semiconductors & Semiconductor Equipment | €2.83T | 74.3x | 0.09 | €115 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
NVIDIA | Xetra | Technology | Semiconductors & Semiconductor Equipment | €2.81T | 74.1x | 0.09 | €114.96 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
NVIDIA | Vienna | Technology | Semiconductors & Semiconductor Equipment | €2.81T | 73.7x | 0.09 | €114.86 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
NVIDIA | Milan | Technology | Semiconductors & Semiconductor Equipment | €2.80T | 74.1x | 0.09 | €114.92 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Astellas Pharma | Frankfurt | Healthcare | Pharmaceuticals | €19.39B | 145.7x | -1.79 | €10.70 | 4.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Eli Lilly and | Xetra | Healthcare | Pharmaceuticals | €762.90B | 116x | 8.63 | €849 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Eli Lilly | Vienna | Healthcare | Pharmaceuticals | €767.38B | 116.1x | 8.63 | €851.10 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Eli Lilly and | Frankfurt | Healthcare | Pharmaceuticals | €768.42B | 117.1x | 8.63 | €855.20 | -0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Daiichi Sankyo | Frankfurt | Healthcare | Pharmaceuticals | €68.67B | 49x | 0.89 | €35.53 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Expedia | Vienna | Consumer Cyclicals | Hotels & Entertainment Services | €15.48B | 22.5x | 18.54 | €121.76 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bristol-Myers | Xetra | Healthcare | Pharmaceuticals | €88.73B | -15.2x | 0.08 | €43.87 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bristol Myers Squibb | Frankfurt | Healthcare | Pharmaceuticals | €87.92B | -15x | 0.08 | €43.80 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Adobe | Frankfurt | Technology | Software & IT Services | €224.49B | 50.4x | 7.98 | €506.60 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Adobe Systems | Vienna | Technology | Software & IT Services | €223.90B | 50.3x | 7.98 | €506.90 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca DRC | Frankfurt | Healthcare | Pharmaceuticals | €235.90B | 40.7x | 9.52 | €76.50 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Meta Platforms | Frankfurt | Technology | Software & IT Services | €1.21T | 26.6x | 0.2 | €476.05 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca | Frankfurt | Healthcare | Pharmaceuticals | €235.90B | 40.7x | 9.52 | €152.75 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Meta Platforms | Vienna | Technology | Software & IT Services | €1.21T | 26.4x | 0.2 | €478.30 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Meta Platforms | Xetra | Technology | Software & IT Services | €1.20T | 26.5x | 0.2 | €478.25 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Meta Platforms | Milan | Technology | Software & IT Services | €1.20T | 26.5x | 0.2 | €478.20 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Astrazeneca PLC | Xetra | Healthcare | Pharmaceuticals | €235.90B | 40.7x | 9.52 | €152.80 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Gilead Sciences | Xetra | Healthcare | Pharmaceuticals | €83.81B | 89.1x | -1.08 | €67.53 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Gilead Sciences | Vienna | Healthcare | Pharmaceuticals | €83.48B | 88.6x | -1.08 | €67.18 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Gilead Sciences | Milan | Healthcare | Pharmaceuticals | €83.76B | 89.1x | -1.08 | €67.55 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Astrazeneca | BATS Europe | Healthcare | Pharmaceuticals | €235.66B | 40.7x | 9.53 | €152.41 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Gilead Sciences | Frankfurt | Healthcare | Pharmaceuticals | €83.76B | 88.9x | -1.08 | €67.27 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca DRC | Vienna | Healthcare | Pharmaceuticals | €235.90B | 40.7x | 9.52 | €77 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca PLC | BATS Europe | Healthcare | Pharmaceuticals | €235.97B | 40.7x | 9.55 | €151.91 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
ServiceNow | Vienna | Technology | Software & IT Services | €154.04B | 148.8x | -7.23 | €752.40 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |